Literature DB >> 23258971

Use of Recombinant Factor VIIa in a Pediatric Patient With Initial Presentation of Refractory Acute Immune Thrombocytopenic Purpura and Severe Bleeding.

Reut Gurion1, Anita Siu, Aaron R Weiss, Margaret Masterson.   

Abstract

Severe bleeding in acute immune thrombocytopenic purpura (ITP) is rare but can cause significant complications to the patient. Here we report the case of a pediatric patient with acute ITP and hematuria refractory to anti-D immune globulin, high dose intravenous immunoglobulin G, and high dose steroids. Her hematuria was successfully treated with recombinant factor VIIa (rFVIIa). While further investigation on the use of rFVIIa in ITP is warranted, this case report contributes to the pediatric literature for its use during the course of an initial presentation of ITP with hemorrhagic complications.

Entities:  

Keywords:  FX, factor X; HPF, high-power field; ITP, immune thrombocytopenic purpura; IVIG, intravenous immunoglobulin G; immune thrombocytopenic purpura; pediatrics; rFVIIa, recombinant factor VIIa; recombinant factor VIIa

Year:  2012        PMID: 23258971      PMCID: PMC3526932          DOI: 10.5863/1551-6776-17.3.274

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  24 in total

1.  Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura.

Authors:  Srdana Culić
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

Review 2.  Differential diagnosis and management of thrombocytopenia in childhood.

Authors:  Rosandra N Kaplan; James B Bussel
Journal:  Pediatr Clin North Am       Date:  2004-08       Impact factor: 3.278

3.  Efficacy and safety of recombinant factor VIIa in the treatment of bleeding episodes in patients with aplastic anemia.

Authors:  A M Al Hammadi; S Sallah
Journal:  J Thromb Haemost       Date:  2007-02       Impact factor: 5.824

Review 4.  NovoSeven as a universal haemostatic agent.

Authors:  U Hedner
Journal:  Blood Coagul Fibrinolysis       Date:  2000-04       Impact factor: 1.276

5.  Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment.

Authors:  C Barnes; V Blanchette; P Canning; M Carcao
Journal:  Transfus Med       Date:  2005-04       Impact factor: 2.019

Review 6.  Current controversies in the management of idiopathic thrombocytopenic purpura during childhood.

Authors:  D Medeiros; G R Buchanan
Journal:  Pediatr Clin North Am       Date:  1996-06       Impact factor: 3.278

7.  Severe bleeding in idiopathic thrombocytopenic purpura.

Authors:  Paula Bolton-Maggs
Journal:  J Pediatr Hematol Oncol       Date:  2003-12       Impact factor: 1.289

8.  Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura.

Authors:  S J Woerner; C F Abildgaard; B N French
Journal:  Pediatrics       Date:  1981-04       Impact factor: 7.124

9.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

10.  Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children.

Authors:  Guy Young; Brian Wicklund; Philip Neff; Chelsea Johnson; Diane J Nugent
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.